Literature DB >> 8306104

Electrophysiological and antiarrhythmic actions of the kappa agonist PD 129290, and its R,R (+)-enantiomer, PD 129289.

M K Pugsley1, D A Saint, M P Penz, M J Walker.   

Abstract

1. The S,S (-)-enantiomer PD 129290, a kappa agonist, and its corresponding inactive R,R (+)-enantiomer (PD 129289) were studied in rat isolated hearts and in intact rats for cardiovascular and antiarrhythmic actions. The electrophysiological actions of PD 129290 were also studied in rat isolated cardiac myocytes using voltage clamp. 2. Ventricular pressure, heart rate and ECG were studied in isolated hearts while blood pressure, heart rate and ECG were studied in pentobarbitone-anaesthetized rats. In the latter, responses to electrical stimulation and coronary occlusion were also investigated. 3. In isolated hearts both enantiomers, over the concentration range 2-16 microM, dose-dependently reduced systolic ventricular pressure and heart rate while prolonging the P-R and QRS intervals of the ECG. 4. At doses of 1-32 mumol kg-1 both enantiomers reduced blood pressure and heart rate in anaesthetized rats. In addition, both enantiomers increased the size of the RSh and increased P-R, QRS, and Q-T intervals of the ECG. The thresholds for premature beats and ventricular fibrillation were dose-dependently increased by PD 129289. At lower doses PD 129290 decreased thresholds. These decreases were blocked by naloxone to reveal underlying increases similar to those seen with PD 129289. Both enantiomers increased refractory periods. 5. Naloxone (8 mumol kg-1) did not alter any of the actions of PD 129290, except to abolish the initial decreases in thresholds in intact rats seen with lower doses of PD 129290. 6. Both enantiomers (2 and 8 mumol kg-1) equally reduced arrhythmias in anaesthetized rats subject to occlusion of a coronary artery. 7. In rat isolated cardiac myocytes 20 microM PD 129290, in the presence and absence of naloxone decreased the amplitude of the transient sodium current by about 50% without affecting the voltage dependence of activation or inactivation of this current.8. The antiarrhythmic actions of both enantiomers appear to primarily result from their Class I(sodium channel blockade) properties which are independent of kappa agonism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306104      PMCID: PMC2175892          DOI: 10.1111/j.1476-5381.1993.tb14004.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Electrically induced arrhythmias in the rat.

Authors:  M J Walker; G N Beatch
Journal:  Proc West Pharmacol Soc       Date:  1988

Review 2.  Pharmacology of opioids.

Authors:  W R Martin
Journal:  Pharmacol Rev       Date:  1983-12       Impact factor: 25.468

3.  Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.

Authors:  M K Pugsley; W P Penz; M J Walker; T M Wong
Journal:  Eur J Pharmacol       Date:  1992-02-25       Impact factor: 4.432

4.  CI-977, a novel and selective agonist for the kappa-opioid receptor.

Authors:  J C Hunter; G E Leighton; K G Meecham; S J Boyle; D C Horwell; D C Rees; J Hughes
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

5.  Highly selective kappa-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4- or -5-substituted-cyclohexyl]arylacetamide derivatives.

Authors:  P R Halfpenny; D C Horwell; J Hughes; J C Hunter; D C Rees
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

6.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia.

Authors:  M J Curtis; M J Walker
Journal:  Cardiovasc Res       Date:  1988-09       Impact factor: 10.787

7.  Responses to ligation of a coronary artery in conscious rats and the actions of antiarrhythmics.

Authors:  K M Johnston; B A MacLeod; M J Walker
Journal:  Can J Physiol Pharmacol       Date:  1983-11       Impact factor: 2.273

8.  The actions of prostaglandins I2 and E2 on arrhythmias produced by coronary occlusion in the rat and dog.

Authors:  T L Au; G A Collins; C J Harvie; M J Walker
Journal:  Prostaglandins       Date:  1979-11

9.  An improved perfusion apparatus for small animal hearts.

Authors:  M J Curtis; B A Macleod; R Tabrizchi; M J Walker
Journal:  J Pharmacol Methods       Date:  1986-02

10.  Anti-arrhythmic activities of opioid agonists and antagonists and their stereoisomers.

Authors:  Y Sarne; A Flitstein; E Oppenheimer
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  8 in total

1.  kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action.

Authors:  S K Joshi; X Su; F Porreca; G F Gebhart
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

2.  Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921.

Authors:  M K Pugsley; A L Goldin
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 3.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  Activation of peripheral opioid receptors has no effect on heart rate variability.

Authors:  Ender Ellidokuz; Dayimi Kaya; Ihsan Uslan; Ataç Celik; Ali Metin Esen; Irfan Barutça
Journal:  Clin Auton Res       Date:  2008-04-30       Impact factor: 4.435

Review 5.  Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Authors:  Leonid N Maslov; Igor Khaliulin; Peter R Oeltgen; Natalia V Naryzhnaya; Jian-Ming Pei; Stephen A Brown; Yury B Lishmanov; James M Downey
Journal:  Med Res Rev       Date:  2016-05-16       Impact factor: 12.944

6.  Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose.

Authors:  Davood Soroosh; Mahbubeh Neamatshahi; Bahram Zarmehri; Samaneh Nakhaee; Omid Mehrpour
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-02-20

7.  The effects of opium on the cardiovascular system: a review of side effects, uses, and potential mechanisms.

Authors:  Samaneh Nakhaee; Saeedeh Ghasemi; Kimiya Karimzadeh; Nasim Zamani; Samaneh Alinejad-Mofrad; Omid Mehrpour
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-04-17

Review 8.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.